Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06136741 · ClinicalTrials.gov registry record · Phase 2

A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis

A Phase 2 study of Moderate-to-Severe Atopic Dermatitis, sponsored by Nektar Therapeutics.

Active
Registry status
Phase 2
Development phase
396
Enrollment target
20
Study locations

NCT06136741 is a Phase 2 study of Moderate-to-Severe Atopic Dermatitis that is active but no longer recruiting, run by Nektar Therapeutics. The registered enrollment target is 396 participants, below the 569-participant average among 4 other Moderate-to-Severe Atopic Dermatitis trials with a reported enrollment target (30% lower). The trial reports 20 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06136741, a Phase 2 study of Moderate-to-Severe Atopic Dermatitis, is active but no longer recruiting, sponsored by Nektar Therapeutics.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
396 participants
Enrollment target
20
Study locations

Study Summary

This is an interventional, randomized, parallel group, treatment, Phase IIb, double blind, 4-arm study to assess the effect of pegylated-recombinant-human interleukin-2 (rezpegaldesleukin) in adult participants with moderate to severe atopic dermatitis. The estimated duration is 15-35 days for screening, an Induction Period of 16 weeks, a Maintenance Period from Week 16-Week 52, and a Posttreatment Follow-Up Period for an additional year up to approximately Week 104 for all patients. Patients with a response at Week 16 (end of induction therapy) will be re-randomized for the maintenance therapy period.

Conditions Studied

Moderate-to-Severe Atopic Dermatitis

Interventions

  • DRUG Placebo
  • DRUG Rezpegaldesleukin

Study Locations (20)

Florida

  • Nektar Investigative Site - Hialeah
  • Nektar Investigative Site - Hollywood
  • Nektar Investigative Site - Miami
  • Nektar Investigative Site - Miami Lakes
  • Nektar Investigative Site - St. Petersburg
  • Nektar Investigative Site - Tampa

California

  • Nektar Investigative Site - Fountain Valley
  • Nektar Investigative Site - Los Angeles
  • Nektar Investigative Site - Los Angeles
  • Nektar Investigative Site - Los Angeles
  • Nektar Investigative Site - Santa Monica

Indiana

  • Nektar Investigative Site - Clarksville
  • Nektar Investigative Site - Indianapolis

Michigan

  • Nektar Investigative Site - Flint
  • Nektar Investigative Site - Troy

Arkansas

  • Nektar Investigative Site - Bryant

Georgia

  • Nektar Investigative Site - Marietta

Kentucky

  • Nektar Investigative Site - Louisville

Nevada

  • Nektar Investigative Site - Las Vegas

Trial Details

FieldValue
Enrollment Target 396 participants
Start Date 2023-11-15
Est. Completion 2026-12-31
Phase Phase 2

Sponsor

Nektar Therapeutics

37 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06136741

The ClinicalTrials.gov registry entry for NCT06136741 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 396 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 569-participant average among 4 other Moderate-to-Severe Atopic Dermatitis trials with a reported enrollment target (30% lower). The listed sponsor is Nektar Therapeutics, which has 37 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Moderate-to-Severe Atopic Dermatitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06136741 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Florida, California, Indiana.

Frequently Asked Questions

What is clinical trial NCT06136741 about?

NCT06136741 is a clinical study titled "A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis". This is an interventional, randomized, parallel group, treatment, Phase IIb, double blind, 4-arm study to assess the effect of pegylated-recombinant-human interleukin-2 (rezpegaldesleukin) in adult participants with moderate to severe atopic dermatitis. The estimated duration is 15-35 days for scre...

What is the current status of trial NCT06136741?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 396 participants. The study started on 2023-11-15. Estimated completion is 2026-12-31.

What conditions does trial NCT06136741 study?

This clinical trial studies the following conditions: Moderate-to-Severe Atopic Dermatitis.

What interventions are being tested in trial NCT06136741?

The interventions under investigation include: Placebo (DRUG), Rezpegaldesleukin (DRUG).

Who is sponsoring clinical trial NCT06136741?

This trial is sponsored by Nektar Therapeutics, which has 37 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06136741 being conducted?

This trial has 20 study locations across Arkansas, California, Florida, Georgia, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Moderate-to-Severe Atopic Dermatitis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Moderate-to-Severe Atopic Dermatitis

All registered trials for this condition

Arkansas

All trials with a study site in Arkansas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.